1000045-29-3

Basic information

• Product Name: N-{(1S)-2-hydroxy-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide
• Synonyms: N-{(1S)-2-hydroxy-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide
• CAS NO: 1000045-29-3
• Molecular Weight: 372.399
• Mol File: 1000045-29-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-{(1S)-2-hydroxy-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{(1S)-2-hydroxy-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide(1000045-29-3)
• EPA Substance Registry System: N-{(1S)-2-hydroxy-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide(1000045-29-3)

Safety Data

• Hazardous Substances Data: 1000045-29-3(Hazardous Substances Data)

Upstream product

• 1000146-73-5 C₉H₁₇NO₃ 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 1000045-30-6 (3S,5S)-5-[(S)-1-amino-2-hydroxyethyl]-3-isopropyltetrahydrofuran-2-one hydrochloride 
• 1000045-28-2 (3S,5S)-5-[(1S)-1-azido-2-benzyloxyethyl]-3-isopropyldihydrofuran-2-one 
• 1056674-54-4 (3S,5S)-5-[(1R)-2-(benzyloxy)-1-hydroxyethyl]-3-isopropyldihydrofuran-2(3H)-one 
• 1187941-31-6 C₂₆H₃₁NO₄ 
• 1000045-24-8 (2S,4E)-6-(benzyloxy)-2-isopropylhex-4-enoic acid 
• 145589-03-3 (S)-4-benzyl-3-(3-methylbutanoyl)oxazolidin-2-one 

Downstream Products

• 1000045-31-7 (3S,5S)-3-isopropyl-5-[(2S)-1-(2-nitrobenzenesulfonyl)aziridine-2-yl]dihydrofuran-2-one 
• 1000045-68-0 (2S,4S,5S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-6-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}hexanamide fumarate 
• 1000048-12-3 (2S,4S,5S)-5-amino-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-4-hydroxy-N-(trans-4-hydroxycyclohexyl)-2-isopropylhexanamide fumarate 
• 1000048-01-0 (2S,4S,5S)-5-amino-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-N-(tetrahydro-2H-pyran-4-yl)hexanamide fumarate 
• 1000048-32-7 (2S,4S,5S)-5-amino-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-N-(pyridin-2-yl)hexanamide fumarate 
• 1000048-38-3 (2S,4S,5S)-5-amino-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-N-(pyridin-3-yl)hexanamide fumarate 
• 1000048-41-8 (2S,4S,5S)-5-amino-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-N-(pyridin-4-yl)hexanamide fumarate 
• 1436430-24-8 methyl 5-[(tert-butoxycarbonyl)amino]-6-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-2,3,5,6-tetradeoxy-2-propan-2-yl-L-lyxo-hexonate 
• 1436430-26-0 tert-butyl (4S,5S)-4-{[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]methyl}-5-[(2S)-2-(methoxycarbonyl)-3-methylbutyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 1436430-30-6 (2S)-2-{[(4S,5S)-3-(tert-butoxycarbonyl)-4-{[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]methyl}-2,2-dimethyl-1,3-oxazolidin-5-yl]methyl}-3-methylbutanoic acid 
• 1436430-33-9 tert-butyl (4S,5S)-4-{[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]methyl}-5-{(2S)-2-[(3-hydroxyadamantan-1-yl)carbamoyl]-3-methylbutyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 

Relevant articles and documents

Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)- 4-hydroxyhexanamides to reduce a cardiac safety issue: Discovery of DS-8108b, an orally active renin inhibitor

With the aim to address an undesired cardiac issue observed with our related compound in the recently disclosed novel series of renin inhibitors, further chemical modifications of this series were performed. Extensive structure-activity relationships studies as well as in vivo cardiac studies using the electrophysiology rat model led to the discovery of clinical candidate trans-adamantan-1-ol analogue 56 (DS-8108b) as a potent renin inhibitor with reduced potential cardiac risk. Oral administration of single doses of 3 and 10 mg/kg of 56 in cynomolgus monkeys pre-treated with furosemide led to significant reduction of mean arterial blood pressure for more than 12 h.

CYCLIC AMINE COMPOUND

The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, -(CH2)a-X1-(CH2)b- (X1: the formula -NH-, -O- or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].